In recent days, the American Tarcine BioMed and POC Medical announced that Tarcine BioMed Limited and POC Medical Systems, which located in Livermore,California, USA, formally signed memorandum on April 20, 2015. They will worktogether to establish the joint venture in China, seeking to combine thereagent products for early screening of cancer and early warning of heart disease researched by Tarcine BioMed with the advanced Pandora CDx platform technology of POC Medical.
POC Medical Systems is known as a diagnosis platform technology company from Livermore, San Francisco bay area, California. The company is committed to develop POCT medical diagnostic devicesand products forearly detection of major human diseases that threatening the patient’s life and health; to provide high-quality, efficient and economical solutions to improvethe services quality of medical care industry and rescue human lives; and to bring good benefits and rewards for investors and partners.
With all the unremitting efforts, Tarcine BioMed finally found an advanced innovative platform technology that can effectively optimize the advantages of their existing products. It is granted in the memorandum that authorized by POC Medical, Tarcine BioMed will have the worldwide exclusive rights to Pandora CDx platform technology to develop early warning products with traces of blood totest cancers as well as myocardial infarction, etc. Sanjeev Saxena, the CEO of POC Medical said: "The signature of memorandum is a real milestone. It is a very important step for POC to build our first joint venture company in one of the world's largest markets."